Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A compound comprising:

(a) a CD1d complex; and

(b) an antibody specific for a cell surface marker or an antigen-binding fragment thereof;

wherein said CD1d complex comprises a CD1d molecule or fragment thereof, ~~and~~ a β2-microglobulin molecule or fragment thereof, and a lipid or glycolipid antigen associated with said CD1d molecule; and wherein said CD1d complex is linked to said antibody or fragment thereof.

2. (Canceled)

3. (Canceled)

4. (Currently Amended) The compound of claim ~~3~~ 1, wherein said antigen is α-GalCer.

5. (Withdrawn, Currently Amended) The compound of claim ~~3~~ 1, wherein said antigen is α-GalCer modified to have a shortened long-chain sphingosine base (C5 vs. C14) and acyl chain (C24 vs. C26)

6. (Withdrawn) The compound of claim 5, wherein said modified α-GalCer is the OCH analog with a long-chain sphingosine base shortened from C14 to C5 and acyl chain from C26 to C24.

7. (Withdrawn) The compound of claim 1, wherein said antibody fragment is a F(ab).

8. (Previously Presented) The compound of claim 1, wherein said antibody fragment is a scFv.

9. (Withdrawn) The compound of claim 1, wherein said antibody is a full-length antibody.

10. (Currently Amended) The compound of any of claims 1 or 4-9, wherein said cell surface marker is a cell surface marker of tumor cells.

11. (Original) The compound of claim 10, wherein said cell surface marker is selected from the group consisting of: CEA, Her2/neu, EGFR type I or type II, CD19, CD20, CD22, Muc-1, PSMA, or STEAP.

12. (Canceled)

13. (Withdrawn) The compound of claim 1, wherein said cell surface marker is a cell surface marker of dendritic cells.

14-16. (Canceled)

17. (Withdrawn) The compound of claim 1, wherein said cell surface marker is a cell surface marker of a target of autoimmune or inflammatory disease.

18-27. (Canceled)

28. (Withdrawn) The compound of claim 1, wherein said cell surface marker is a cell surface marker of an infected cell or tissue.

29-35. (Canceled)

36. (Withdrawn) The compound of claim 1, wherein said CD1d molecule is attached to the heavy chain of said antibody.

37. (Withdrawn) The compound of claim 1, wherein said CD1d molecule is attached to the light chain of said antibody.

38. (Withdrawn) The compound of claim 1, wherein said β2 microglobulin molecule is attached to the heavy chain of said antibody.

39. (Withdrawn) The compound of claim 1, wherein said β2 microglobulin molecule is attached to the light chain of said antibody.

40. (Previously Presented) The compound of claim 1, wherein the CD1d complex is linked in a fusion protein with the antibody or fragment thereof.

41. (Withdrawn) The compound of claim 1, wherein said CD1d complexes are attached to said antibody through a linker sequence.

42-45. (Canceled)

46. (Withdrawn) A method of inducing an anti-tumor response in a mammal, comprising administering the compound of claim 49 to said mammal.

47-48. (Canceled)

49. (Previously Presented) The compound of claim 11, wherein said cell surface marker is Her2/neu.

50. (Previously Presented) The compound of claim 1, wherein the CD1d molecule or fragment thereof of said CD1d complex comprises the extracellular portion of CD1d.

51. (Previously Presented) The compound of claim 50, wherein said extracellular portion comprises amino acids 1-297 of the amino acid sequence of SEQ ID NO: 40.

52. (Previously Presented) The compound of claim 8, wherein the variable light domain and the variable heavy domain of said scFv are linked by a peptide bridge.

53. (Withdrawn) The compound of claim 8, wherein the variable light domain and the variable heavy domain of said scFv are linked by one or more disulfide bonds.

54. (Previously Presented) The compound of claim 40, wherein the CD1d molecule of said CD1d complex is fused to said antibody or fragment thereof.

55. (Previously Presented) The compound of claim 54, wherein the CD1d molecule of said CD1d complex is linked to the amino terminus of the antibody or fragment thereof.

56. (Withdrawn) The compound of claim 54, wherein the CD1d molecule of said CD1d complex is linked to the carboxyl terminus of the antibody or fragment thereof.

57. (Previously Presented) The compound of claim 54, wherein a short linker amino acid sequence of from about 3 to about 30 amino acids is situated between the CD1d molecule of said CD1d complex and the antibody or fragment thereof.

58. (Withdrawn) The compound of claim 57, wherein said short linker amino acid sequence comprises the sequence of SEQ ID NO: 1.

59. (Previously Presented) The compound of claim 57, wherein said short linker amino acid sequence comprises the sequence of SEQ ID NO: 2.

60. (Withdrawn) The compound of claim 40, wherein the β2-microglobulin molecule of said CD1d complex is fused to said antibody or fragment thereof.

61. (Withdrawn) The compound of claim 60, wherein the β2-microglobulin molecule of said CD1d complex is linked to the amino terminus of the antibody or fragment thereof.

62. (Withdrawn) The compound of claim 60, wherein the β2-microglobulin molecule of said CD1d complex is linked to the carboxyl terminus of the antibody or fragment thereof.

63. (Withdrawn) The compound of claim 60, wherein a short linker amino acid sequence of from about 3 to about 30 amino acids is situated between the β2-microglobulin molecule of said CD1d complex and the antibody or fragment thereof.

64. (Withdrawn) The compound of claim 63, wherein said short linker amino acid sequence comprises the sequence of SEQ ID NO: 1.

65. (Withdrawn) The compound of claim 63, wherein said short linker amino acid sequence comprises the sequence of SEQ ID NO: 2.